Morgan Stanley analyst Tejas Savant maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and maintains the target price at $670.
According to TipRanks data, the analyst has a success rate of 38.0% and a total average return of -6.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
Thermo Fisher's recent financial performance met expectations in a context of high anticipation. Solid execution was noted in a challenging demand climate for tools, with uncertainty remaining regarding the timing of demand improvement.
The company's third-quarter earnings presentation was deemed more encouraging than the actual results, and the analyst continues to hold a positive outlook on the stock. The Life Sciences Solutions segment is experiencing bioproduction momentum, and the Laboratory Products and Biopharma Services segment appears to be unaffected by a biotech slowdown.
The firm observes that Thermo Fisher's core growth is showing a consistent improvement on a quarter-over-quarter basis, with forecasts suggesting a slight increase to approximately 2.5% in Q4. Expectations from the market for a 5% core growth by 2025 are also perceived as reasonable and justifiable. The firm maintains its appreciation for Thermo Fisher's resilient business model and the flexibility provided by its balance sheet.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析师Tejas Savant维持$赛默飞世尔 (TMO.US)$买入评级，维持目标价670美元。
根据TipRanks数据显示，该分析师近一年总胜率为38.0%，总平均回报率为-6.5%。
此外，综合报道，$赛默飞世尔 (TMO.US)$近期主要分析师观点如下：
赛默飞世尔最近的财务表现符合预期，处于高度期待的环境中。在需求工具挑战性气候下，实现稳健执行，然而关于需求改善时机仍存在不确定性。
公司第三季度收益报告被认为比实际结果更令人鼓舞，分析师继续持有股票乐观态度。生命科学解决方案部门正在经历生物生产势头，而实验室产品和生物制药服务部门似乎不受生物技术减速影响。
该公司观察到赛默飞世尔核心增长在季节调整过程中持续改善，预测显示第四季度核心增长略有增加，约为2.5%。市场对2025年预计5%核心增长的期望被认为合理和合理。该公司坚持赛默飞世尔坚韧的业务模式以及其资产负债表提供的灵活性。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
